Dileme pri zdravljenju alzheimerjeve bolezni
Abstract
Izhodišča: Kljub jasno postavljenim merilom s strani Zavoda za zdravstveno zavarovanje, po katerih lahko pričnemo zdravljenje bolnikov z Alzheimerjevo boleznijo, se v praksi pojavljajo mnoge dileme: kdaj pričeti in predvsem kdaj zaključiti zdravljenje, kolikšen naj bo odmerek, ali je zdravljenje sploh učinkovito in zato smiselno.
Zaključki: V Sloveniji čedalje več bolnikov in/ali njihovih svojcev poišče pomoč v začetnih stadijih demence, vendar pa si bo kljub temu še naprej potrebno prizadevati za boljšo obveščenost in izobraževanje laikov pa tudi strokovnih delavcev. Pravilna diagnoza je temelj uspešnega zdravljenja. Zgodnja diagnoza Alzheimerjeve bolezni ni vedno enostavna zaradi vpliva telesnih bolezni, duševnih motenj ter iatrogenih ???? vzrokov upada spoznavnih sposobnosti. V pomoč so lahko merila za klinično diagnozo Alzheimerjeve bolezni. Ob tem se pogosto srečujemo s klinično slabo opredeljenim področjem mešane etiologije vaskularne demence in Alzheimerjeve bolezni. V prispevku so opisane lastnosti in pomanjkljivosti uporabe priporočenega Kratkega preizkusa spoznavnih sposobnosti. Zdravljenje naj bi, ob upoštevanju meril Zavoda za zdravstveno zavarovanje, začeli čim prej. Prekinitev zdravljenja je prepuščena individualni presoji posameznika, smiselna pa je zaradi izraženosti neželenih učinkov, ob pomanjkanju učinkovitega delovanja in v poznem stadiju bolezni.
Downloads
References
National Institute for Clinical Excellence. Appraisal consultation document: Alzheimer’s disease – donepezil, rivastigmine, galantamine and memantine (review). National Institute for Health and Clinical Excellence Sep 2005. Dosegljivo na: www.nice.org.uk/page.aspx?o=245908
Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer’s disease (appraisal consultation). National Institute for Health and Clinical Excellence Feb 2006. Dosegljivo na: www.nice.org.uk/page.aspx?o=288826.
Bond J, Stave C, Sganga A, O’Connell B, Stanley RL. Inequalities in dementia care across Europe: key findings of the Facing Dementia Survey. Internati J Clin Practice 2005; 59 Suppl 146: 8–14.
Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56(9): 1154–66.
Emre M. Revised EFNS guideline on the management of Alzheimer’s disease and related disorders: Recommendations for treatment. Eur J Neurol 2005; 12 Suppl 2: 190.
Birks JS, Harvey R. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev 2003; 3: CD001190.
Loy C, Schneider L. Galantamine for Alzheimer’s disease. Cochrane Database Syst Rev 2004; 4: CD001747.
Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev 2000; 4: CD001191.
Areosa SA, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev 2005; 2: CD003154.
Alzheimer Europe. Alzheimer Europe response to the preliminay NICE recommendations. Alzheimer Europe Sep 2005. Dosegljivo na: www.alzheimer-europe.org/?lm2=ABDFA1AD8BF7
Jenike MA. Geriatric psychiatry and psychopharmacology. Chicago: Year Book Medical Publishers; 1990.
World Health Organization. The ICD-10 classification of mental and behavioural disorders. Geneva: World Health Organization; 1992.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM IV. Washington: American Psychiatric Association; 1994.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health & Human Services Task Force on Alzheimer’s disease. Neurology 1984: 34: 939–44.
Roman GC, Wilkinson DG, Doody RS, Black SE, Salloway SP, Schindler RJ. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. Dement Geriatr Cogn Disord 2005; 20(6): 338–44.
Small G, Erkinjuntti T, Kurz A, Lilienfeld S. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer’s disease with cerebrovascular disease. CNS Drugs 2003; 17(12): 905–14.
Vincent S, Lane R. Rivastigmine in vascular dementia. Int Psychogeriatr 2003;15 Suppl 1: 201–5.
Wilcock G, Mobius HJ, Stoffler A; MMM 500 group. A doubleblind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002; 17: 297–305.
Areosa SA, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev 2005; 3: CD003154.
Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane Database Syst Rev 2004; 1: CD004395.
Craig D, Birks J. Rivastigmine for vascular cognitive impairment. Cochrane Database Syst Rev 2005; 2: CD004744.
Jellinger KA. The pathology of ischemic-vascular dementia: an update. J Neurol Sci 2002; 203–204: 153–7.
Simard M, van Reekum R. The acetylcholinesterase inhibitors for treatment of cognitive and behavioral symptoms in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci 2004; 16: 409–25.
McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031–6.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
